Progress and challenges in the therapy of adult acute lymphoblastic leukemia

Current Opinion in Hematology

Volumn 10, Issue 4, 2003, Pages 284-289

  Kebriaei, Partow ^a   Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; IMATINIB; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DECISION MAKING; DISEASE COURSE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RESPIRATORY DISTRESS; REVIEW; TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; NEOPLASM, RESIDUAL; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0037632760     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200307000-00006     Document Type: Review

References (20)

1. Annino L, Vegna ML, Camera A, et al.: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002, 99:863-871. This is a large, multicenter, randomized clinical trial with a long follow-up that tested minor alterations in induction and postremission intensification therapy.
2. Linker C, Damon L, Ries C, et al.: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:2464-2471. This single-institution study has a long follow-up and demonstrates the benefit of high-dose methotrexate for postremission therapy.
3. Todeschini G, Tecchio C, Meneghini V, et al.: Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia 1998, 12:144-149.
4. Takeuchi J, Kyo T, Naito K, et al.: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL 93 study. Leukemia 2002, 16:1259-1266.
5. Sotomayer EM, Piantadosi S, Miller CB, et al.: Long-term follow-up of intensive Ara-C based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy. Leuk Res 2002, 26:461-471.
6. Powles R, Sirohi B, Treleaven J, et al.: The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 2002, 100:1641-1647.
7. Ooi J, Iseki T, Takahashi S, et al.: A clinical comparison of unrelated cord blood transplantation and unrelated bone marrow transplantation for adult patients with acute leukaemia in complete remission. Br J Haematol 2002, 118:140-143.
8. Surapaneni UR, Cortes JE, Thomas D, et al.: Central nervous system relapse in adults with acute lymphoblastic leukemia. Am Cancer Soc 2002, 773-779. Although a retrospective series, this is one of the few recent analyses of CNS recurrences in adult ALL.
9. Cortes J, O'Brien SM, Pierce S, et al.: The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995, 86:2091-2097.
10. Ritchey AN, Pollock BH, Lauer SJ, et al.: Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1999, 17:3745-3752.
11. Yokota H, Tsuno NH, Tanaka Y, et al.: Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay. Leukemia 2002, 16:1167-1175.
12. Sanchez J, Serrano J, Gomez P, et al.: Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 2002, 116:686-694.
13. Mortuza FY, Papaioannou M, Moreira IM, et al.: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:1094-1104. Prospective assessment of MRD by clonal IGH rearrangements correlated with clinical outcome in 85 adults treated on the United Kingdom Acute Lymphoblastic Leukemia protocol UKALL XII.
14. Ribera JM, Ortega JJ, Oriol A, et al.: Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 2002, 87:154-166.
15. Gleissner B, Gokbuget N, Bartram CR, et al.: Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002, 99:1536-1543. This is the first large study to evaluate prospectively the prognostic implications of BCR-ABL in adults in a multicenter trial.
16. Dombret H, Gabert J, Boiron JM, et al.: Outcome of treatment in adults with Philadelphia chromosome positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial. Blood 2002, 100:2357-2366. This large, multicenter, prospective study with a long follow-up confirms the important role of SCT for patients with Ph+ ALL.
17. Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965-1971. This clinical trial evaluates the novel agent, imatinib mesylate, in Ph+ ALL.
18. Scheuring UJ, Pfeifer H, Wassmann B, et al.: Early minimal disease analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood 2003, 101:85-90.
19. Hofmann WK, de Vos S, Elashoff D, et al.: Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 2002, 359:481-486.
20. Ferrando AA, Neuberg DS, Staunton J, et al.: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002, 1:75-87.